The Filing Desk

Caris Life Sciences vs NeoGenomics Laboratories

Caris Life Sciences CAI · NeoGenomics Laboratories NEO · Health Care Services

Caris Life Sciences reported revenue of $812 million in fiscal 2025, about the same as NeoGenomics Laboratories' $727 million in fiscal 2025. Caris Life Sciences' revenue grew 97.0% in its latest year, and NeoGenomics Laboratories' grew 10.1%. Caris Life Sciences had an operating margin of 5.6%, against -15.9% at NeoGenomics Laboratories. Free cash flow was $67 million at Caris Life Sciences and −$22 million at NeoGenomics Laboratories.

Side by side

Caris Life SciencesNeoGenomics Laboratories
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$812M$727M
Revenue growth97.0%10.1%
Revenue growth a year, last 5 years—10.4%
Gross margin—43.2%
Operating margin5.6%−15.9%
Net margin−8.4%−14.8%
Free cash flow$67M−$22M
Free cash flow margin8.2%−3.0%
Return on capital—−8.8%
Net debt to EBITDA−6.2x—
Dividends and buybacks$0M$0M
Change in diluted share count371.0%1.1%
Last close$18.54$15.09
P/E at the last close——
Insider trades, last 12 monthsbought $1.5 million, sold $28.9 millionsold $967,816
Piotroski F-score—5 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Caris Life SciencesNeoGenomics Laboratories
Operating margin
Percent of revenue
Caris Life SciencesNeoGenomics Laboratories
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Caris Life SciencesNeoGenomics Laboratories

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Caris Life Sciences and NeoGenomics Laboratories pages.